The practising optometrist’s point of entry to the most relevant studies, research papers, reviews and conference proceedings, compiled by Dr Laura Downie
Structure loss precedes function loss. This case study highlights the need for careful stereoscopic nerve examination.
MIGS is a recently-coined acronym to include several modern operations or devices that cause minimal or no disruption to the conjunctiva and use an ab interno approach to glaucoma treatment.
Efron, Morgan and Woods analyse the findings of their 15th annual survey of Australian contact lens prescribing habits.
Dr Ben Ashby offers the key take-away messages on diagnosis and management from the International Dry Eye Workshop.
A new treatment option is now available for meibomian gland dysfunction.
Treatment with androgen or oestrogen shows promise and may play an important role in dry eye management in the future.
Orthokeratology treated corneal contour can be simulated with a soft lens for the purpose of myopia control.
The outcome measure for pterygium surgery is now cosmesis, not recurrence.
The practising optometrist’s point of entry to the most relevant studies, research papers, reviews and conference proceedings, compiled by Dr Laura Downie.
If you stick it in your eye, biocompatibility is important, so explore the polarising issue of corneal staining.
Optometrists endorsed to prescribe medicines can prescribe any drug in the list approved by the Optometry Board of Australia. This list is found in the Optometry Endorsement Scheduled Medicines Registration Standard (Table 1). Many of the medicines optometrists are authorised to prescribe are also eligible for PBS subsidy for eligible patients. See the Pharmaceutical Benefits Scheme list.
Optometry’s vital role in shared care of patients is clear in the newly-revised clinical guidelines ‘Examination and management of patients with diabetes’.
The optometrist’s ability to collaborate with other health-care professionals is critical in the management of diabetic patients.
Non-invasive techniques to analyse vascular, neural and structural developments as ocular signs of Alzheimer’s disease are being investigated by a University of Melbourne group.